Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

BIV201

Peptide · Agonist of vasopressin V1a receptor (AVPR1A) · developed by BioVie

Phase 2 Most advanced trial (none active)

BIVI Developer

1 Registered trials

What is BIV201?

BIV201 (terlipressin diacetate) is a vasopressin V1a receptor agonist peptide administered as a continuous infusion. It is studied in decompensated cirrhosis with ascites.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as: terlipressin diacetate
Drug type: Peptide
Targets: vasopressin V1a receptor (AVPR1A)
Mechanism: Agonist of vasopressin V1a receptor (AVPR1A)
Pathways: vasoconstriction
Therapy area: Gastroenterology
Developer: BioVie Inc. (BIVI)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 2

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT04112199	Phase 2	Ascites	Terminated	BIVI

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

AscitesDecompensated Cirrhosis

Other drugs acting on AVPR1A

Conivaptan FDA approved

More from BioVie

Bezisterim Phase 3

Sources

ClinicalTrials.gov NCT04112199

Updated Oct 3, 2026. Something wrong or missing? Report it on the BIVI page.

Follow BIVI, the company behind BIV201

See BIVI's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

BIVI catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z